Long-term retention rates of adalimumab and infliximab in non-infectious intermediate, posterior, and panuveitis

The aim of the present study was tocompare long-term adalimumab (ADA) and infliximab (IFX) retention rates in patients with intermediate, posterior, or panuveitis. Additional aims are as follows: (i) to identify any difference in the causes of treatment discontinuation between patients treated with ADA and IFX; (ii) to assess any impact of demographic features, concomitant treatments, and different lines of biologic therapy on ADA and IFX retention rates; and (iii) to identify any correlation between ADA and IFX treatment duration and the age at uveitis onset, the age at onset of the associated systemic diseases, and the age at the start of treatment. Clinical, therapeutic, and demographic data from patients with non-infectious intermediate, posterior, or panuveitis treated with ADA or IFX were retrospectivelycollected. Kaplan-Meier plot and log-rank (Mantel-Cox) test were used to assess survival curves. One hundred eight patients (188 eyes) were enrolled; in 87 (80.6%) patients, uveitis was associated with a systemic disease. ADA and IFX were administered in 62 and 46 patients, respectively. No statistically significant differences were identified between ADA and IFX retention rates (p value=0.22). Similarly, no differences were identified between ADA and IFX retention rates in relation to gender (p value=0.61 for males, p value=0.09 for females), monotherapy (p value=0.08), combination therapy with conventional disease-modifying antirheumatic drugs (log-rank p value=0.63), and different lines of biologic therapy (p value=0.79 for biologic-naive patients; p value=0.81 for subjects previously treated with other biologics). In conclusion,ADA and IFX have similar long-term retention rates in patients with non-infectious intermediate, posterior, and panuveitis. Demographic, clinical, and therapeutic features do not affect their long-term effectiveness.